Immunovant (IMVT) Other financing activities (2019 - 2026)
Immunovant's (IMVT) quarterly Other financing activities came in at $3.6 million in Q1 2026, up 282.17% YoY from $931000.0 in Q1 2025, and down 83.05% on a QoQ basis from $21.0 million in Q4 2025.
Immunovant (IMVT) Other financing activities (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Other financing activities data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Other financing activities rose 282.17% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.1 million (up 982.23% YoY) and the FY2026 annual result came in at $52.1 million, up 982.23% from the prior year.
- Other financing activities retreated to $3.6 million in Q1 2026, from $21.0 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $24.6 million in Q3 2025 to a low of $21000.0 in Q2 2022.
- A 5-year average of $4.0 million and a median of $910500.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities plunged 83.09% — and 2023, when it jumped 4138.1%.
- Tracing IMVT's Other financing activities over 5 years: stood at $403000.0 in 2022, then soared by 671.96% to $3.1 million in 2023, then decreased by 20.8% to $2.5 million in 2024, then surged by 752.07% to $21.0 million in 2025, then sank by 83.05% to $3.6 million in 2026.
- The last three Other financing activities figures came in at $3.6 million (Q1 2026), $21.0 million (Q4 2025), and $24.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.10 Mn |
| Jun 30, 2026 | 20.10 Mn |
| Mar 31, 2026 | 3.56 Mn |
| Mar 31, 2026 | 3.56 Mn |
| Dec 31, 2025 | 21.00 Mn |
| Dec 31, 2025 | 21.00 Mn |
| Sep 30, 2025 | 24.60 Mn |
| Sep 30, 2025 | 24.60 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | 931,000.00 |
| Mar 31, 2025 | 931,000.00 |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 730,000.00 |
| Sep 30, 2024 | 730,000.00 |
| Jun 30, 2024 | 686,000.00 |
| Jun 30, 2024 | 686,000.00 |
| Mar 31, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |